Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Non-Malignant Blood Disorders

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

Am J Hematol

Risitano AM, Iacobelli S, Kulasekararaj A, van Os M, Terwel SR, Tuffnell J, Piepenbroek B, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Trikha R, Gandhi S, Raiola AM, Daenen LGM, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Paola Iori A, Barberi W, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, de Fontbrune FS, Frieri C, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Marotta S, Cacace F, Laurino M, Passweg JR, Socié G, Mufti GJ, Dufour C, Peffault de Latour R, Severe Aplastic Anaemia Working Party of the EBMT

doi: 10.1002/ajh.70445

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Skin Cancer

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Lancet Oncol

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV

doi: 10.1016/S1470-2045(25)00709-0

Leukemia

Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study

Leukemia

Nielsen CG, Als-Nielsen B, Albertsen BK, Davídsson ÓB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andrés-Jensen L

doi: 10.1038/s41375-026-02873-x

CHICAGO 2026

Lymphoma

Liso-cel achieved high response rates in patients with R/R mantle cell lymphoma treated in routine clinical practice

ASH 2025

Multiple Myeloma (MM)

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

Gynecologic Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

★ 3 Recommended and commented by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL

doi: 10.1016/S1470-2045(25)00379-1

COMMENTED

Genitourinary Cancer

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Clin Oncol

Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group

doi: 10.1200/JCO-25-01324

Gastrointestinal Cancer

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

Lancet Oncol

Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A, CARES-310 Study Group

doi: 10.1016/S1470-2045(25)00543-1

Related content

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study

Liso-cel achieved high response rates in patients with R/R mantle cell lymphoma treated in routine clinical practice

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study